Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Femara (Letrozole) Plus Ribociclib (LEE011) or Placebo as Neo-adjuvant Endocrine Therapy for Women With ER-positive, HER2-negative Early Breast Cancer

Next Previous
Search
Trial Profile

Femara (Letrozole) Plus Ribociclib (LEE011) or Placebo as Neo-adjuvant Endocrine Therapy for Women With ER-positive, HER2-negative Early Breast Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ribociclib (Primary) ; Letrozole
  • Indications Early breast cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms FELINE

    • Most Recent Events

    • 01 Aug 2021 Results (n=7) of a proof of principle study assessing whether Diffuse optical tomography breast imaging system-derived measurements are modifiable with targeted therapies ; patients were enrolled from three clinical studies: NCT02598557, NCT01319539 and NCT02712723 published in the Breast Cancer Research and Treatment
    • 24 Jun 2021 According to a City of Hope National Medical Center media release, City of Hope-Led Research studied the evolution of the DNA and RNA in breast tumor cells of postmenopausal women with ER+ breast cancer who were enrolled in this study.
    • 31 May 2020 Primary endpoint has not been met. (Rate of Pre-operative Endocrine Prognostic Index (PEPI) score 0 at surgery between ribociclib containing arms (combined) vs letrozole alone arm)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top